Diapositiva. 8
Farmacia. Otros posibles roles
- Seguimiento personalizado de la prescripción
- Reporte de pacientes que no compran sus medicamentos
- Creación de espacios de comprobación de peso corporal
- Entrenamiento del personal en técnicas de medida de la presión arterial
- Orientación al paciente hipertenso
- Venta de dispositivos automáticos para medir la presión arterial
Diapositiva. 1
El control de la Hipertensión Arterial en Cuba.
Principales desafíos
Dra. Yamilé Valdés González
Especialista de Medicina Interna
Profesora Auxiliar
Jefa del Laboratorio docente de MAPA “Dr. Germinal Alvarez Batard”. Hospital Universitario “General Calixto García” 2016.
Miembro de la Comision Nacional Asesora para el Diagnstico y Tratamiento de la Hipertension arterial.
A Possible Interaction Between Systemic and Renal Angiotensinogen in the Control of Blood Pressure
Por: Nirupama Ramkumar, Deborah Stuart, Jian Ying y Donald E. Kohan. American Journal of Hypertension, Volume 26, Issue 4, Pp. 473-480.
Angiotensinogen (AGT) is synthesized in the liver and proximal tubule. AGT overexpression at either site might increase blood pressure (BP). We used transgenic mice with AGT overexpression in proximal tubule (K), liver (L), or both sites (KL) to determine the relative contributions of hepatic- and proximal tubule–derived AGT in modulating BP. Mice with liver AGT overexpression manifest salt-sensitive hypertension, whereas mice with renal AGT overexpression are hypertensive regardless of salt intake. Systemic AGT may stimulate endogenous renal AGT synthesis during high sodium intake, leading to hypertension in L mice. [Actualizado: 3 de junio 2013]
Esta sección expone trabajos actuales, de carácter investigativo sobre la hipertensión arterial.
How important is it to control nocturnal hypertension with angiotensin II type 1 receptor blockers?
Por: Shin-ichiro Miura y Keijiro Saku. Hypertension Research (2013) 36, 194–195.
Better blood pressure (BP) control is associated with remarkable clinical benefits with regard to cardiovascular (CV) and renal protection. Patients with chronic kidney disease (CKD) are at significantly higher risk of CV disease (CVD),1 and patients with overt proteinuria as well as albuminuria without a reduction in the estimated glomerular filtration rate (eGFR) are also at significantly higher risk.1 In addition, proteinuria or albuminuria itself should be a target for reducing hard end points. Angiotensin II (Ang II) type 1 (AT1) receptor blockers (ARBs) are highly selective for the AT1 receptor and block the deleterious effects of Ang II.2 ARBs clearly decrease proteinuria and protect the kidneys.3 A nocturnal increase in BP on ambulatory monitoring is superior to office BP for predicting a worsening of albuminuria in elderly individuals with type 2 diabetes. [Actualizado: 11 de marzo 2013]
Comentarios recientes